Morgan Stanley maintains Sana Biotechnology at Overweight, raises price target to $13 from $12

Morgan Stanley kept its Overweight rating on Sana Biotechnology and increased its price target to $13 from $12, citing an 8.3% increase. The new target suggests a 543.6% upside from the Nov 13 close of $2.02.

Original reporting
Published Nov 16, 2026, 3:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains Sana Biotechnology at Overweight, raises price target to $13 from $12 — source image
Decision brief

The 30-second read

$SANABullishMed
01

Why it matters

The new target implies a 543% upside from recent close, which could attract speculative buying.

02

Market read

SANA may see short-term price movement driven by the upgraded target.

03

What to watch

Potential dilution from future financing rounds.

Relevance 6/10Novelty 7/10Timing: today

Background

Analyst rating updates are common catalysts for small-cap biotech stocks.

Company-level read

Ticker impact

$SANABullishMedium confidence
Context

Morgan Stanley raised Sana Biotechnology's price target to $13 from $12.

Expected impact

likely upward pressure as investors price in higher target

Evidence & confidence

Target raise signals improved outlook, prompting buying interest.

Market effects

May lift sentiment in the biotech sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

Target raise could be premature if upcoming trial data disappoints.

Key entities

  • Morgan Stanley

    Maintains Overweight rating on SANA.

Related articles

$SANAMed

Wedbush cuts Sana Biotechnology stock price target on model changes

Wedbush reduced its price target for Sana Biotechnology (NASDAQ:SANA) to $10 from $22, maintaining an Outperform rating. The change reflects model adjustments, excluding hidradenitis suppurativa and updating financing assumptions. Sana's shares have fallen 42% over the past year, trading at $2.40. The company reported a narrower-than-expected Q2 loss of $0.13 per share and holds $160.5 million in cash.

$SANAHighAI 8/10

Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials

Sana Biotechnology (SANA) reported Q3 2026 net income of $20.4M, with R&D expenses rising to $33.9M. The company has $121.7M in cash, expecting a runway into mid-2027. SANA advanced cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma, targeting clinical trials in 2026-2027. UP421 showed long-term survival in type 1 diabetes study. SANA stock is up 1.75% to $2.38.

$SANAHigh

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on pu

$AVAIMedAI 8/10

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.

$SANAMed

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continu